# RUFY4

## Overview
RUFY4 is a gene that encodes the protein RUN and FYVE domain containing 4, which is involved in various cellular processes, particularly in autophagy and endosomal trafficking. The protein is characterized by the presence of distinct domains, including an N-terminal RUN domain, a coiled-coil domain, and a C-terminal FYVE domain, which facilitate its interactions with small GTPases and phosphatidylinositol 3-phosphate (PI(3)P) on endosomal membranes. These interactions are crucial for the protein's role in endo-lysosomal membrane dynamics and autophagy regulation. RUFY4 is expressed at low levels in most tissues but is upregulated in specific immune cells such as dendritic cells and alveolar macrophages under certain conditions, indicating its involvement in immune responses and cellular homeostasis (Terawaki2015RUN; Char2020The; Kim2024RUFY4).

## Structure
RUFY4 is a protein characterized by several distinct domains that contribute to its function in cellular processes. It contains an N-terminal RUN domain, which is crucial for interactions with small GTPases such as Rab7 and ARL8, facilitating endosomal trafficking and lysosome tethering (Terawaki2015RUN; Kim2024RUFY4). The RUN domain also interacts with LAMP2, and its deletion reduces these interactions, highlighting its importance in endo-lysosomal membrane dynamics (Kim2024RUFY4).

The protein also features a coiled-coil (CC) domain, which is responsible for RUFY4 homo-dimerization and affects its interaction with Rab7 and LAMP2 (Kim2024RUFY4). This domain is essential for the protein's structural stability and function in endosomal trafficking.

At the C-terminal, RUFY4 has a FYVE domain, which binds to phosphatidylinositol 3-phosphate (PI(3)P) on endosomal membranes, playing a critical role in endo-lysosomal membrane binding and autophagy regulation (Kim2024RUFY4; Terawaki2015RUN). The FYVE domain's interaction with PI(3)P is crucial for the protein's localization to specific cellular compartments.

RUFY4 is expressed at low levels in most tissues, with higher expression in the lungs and lymphoid organs, and is strongly induced in dendritic cells and alveolar macrophages under certain conditions (Char2020The). The protein's structure and domain organization suggest its involvement in intracellular trafficking and immune responses.

## Function
The RUFY4 gene encodes a protein that plays a significant role in autophagy and lysosomal function in human cells. RUFY4 acts as a positive regulator of autophagy by enhancing the formation and growth of autophagosomes, which are essential for the degradation and recycling of cellular components. This process is facilitated through its interaction with Rab7 and other Rab proteins, which regulate membrane dynamics and promote the clustering and tethering of lysosomes, enabling their fusion with autophagosomes (Char2020The; Terawaki2015RUN).

RUFY4 is also involved in the degradation of autophagic substrates, such as damaged mitochondria and intracellular bacteria, particularly in phagocytic cells. It interacts with the GTP-bound form of ARL8, suggesting a role as a dynein-dynactin adaptor, which influences lysosome positioning and motility (KerenKaplan2021RUFY3). The protein is primarily expressed in lung and lymphatic organs, as well as in dendritic cells and macrophages, where it contributes to immune responses by enhancing autophagic flux and antigen presentation (Char2020The; Terawaki2015RUN). RUFY4's activity is crucial for maintaining cellular homeostasis and immune regulation, particularly in response to interleukin-4 (IL-4) (Terawaki2015RUN).

## Clinical Significance
Alterations in the expression of the RUFY4 gene have significant clinical implications, particularly in the context of clear cell renal cell carcinoma (ccRCC). RUFY4 is upregulated in ccRCC and is associated with high immune infiltration of regulatory T cells (Tregs) and T follicular helper cells (TFHs). This upregulation correlates with poorer overall survival and advanced clinical stages, making RUFY4 a potential prognostic biomarker for ccRCC. Its expression levels can predict the responsiveness of tumors to immune checkpoint blockade (ICB) immunotherapy, especially when combined with PD-L1 expression, indicating its role in immune modulation within the tumor microenvironment (Miao2022As).

In addition to its role in cancer, RUFY4 is involved in bone resorption processes. It interacts with Rab7 and LAMP2 to mediate lysosomal trafficking in osteoclasts. Deletion of RUFY4 in mouse models results in reduced bone resorption and preservation of bone mass, suggesting its potential as a therapeutic target for conditions like osteoporosis, characterized by excessive osteoclast activity (Kim2024RUFY4).

RUFY4 also plays a role in immune responses, particularly in dendritic cells, where it enhances autophagy and lysosome tethering in response to interleukin-4. This function is crucial for antigen presentation and controlling intracellular bacterial infections (Terawaki2015RUN).

## Interactions
RUFY4 interacts with several proteins, playing a significant role in cellular processes such as autophagy and endolysosomal transport. It acts as an effector of the small GTPase ARL8, facilitating the coupling of endolysosomes to the dynein-dynactin motor complex. This interaction is crucial for the retrograde transport of endolysosomal vesicles, particularly in neuronal cells, where it aids in the movement of these vesicles from the axon to the soma (KerenKaplan2022RUFY3).

RUFY4 also interacts with Rab7, a small GTPase involved in endosomal trafficking. This interaction promotes the fusion of late endosomes with lysosomes, a process essential for lysosomal secretion in osteoclasts and autophagy regulation in dendritic cells (Terawaki2015RUN; Kim2024RUFY4). RUFY4's role in autophagy is further supported by its association with phosphatidylinositol-3-phosphate (PtdIns(3)P)-containing organelles, where it competes with Rubicon for binding to Rab7, influencing autophagosome and lysosome dynamics (Terawaki2015RUN).

These interactions highlight RUFY4's involvement in critical cellular pathways, including immune responses and bone resorption, making it a potential target for therapeutic interventions in related diseases (Terawaki2015RUN; Kim2024RUFY4).


## References


1. (KerenKaplan2021RUFY3) RUFY3 and RUFY4 are ARL8 effectors that couple lysosomes to dynein-dynactin. This article has 1 citations.

[2. (Miao2022As) Daojia Miao, Jian Shi, Zhiyong Xiong, Wen Xiao, Xiangui Meng, Qingyang Lv, Kairu Xie, Hongmei Yang, and Xiaoping Zhang. As a prognostic biomarker of clear cell renal cell carcinoma rufy4 predicts immunotherapy responsiveness in a pdl1-related manner. Cancer Cell International, February 2022. URL: http://dx.doi.org/10.1186/s12935-022-02480-7, doi:10.1186/s12935-022-02480-7. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12935-022-02480-7)

[3. (Char2020The) Rémy Char and Philippe Pierre. The rufys, a family of effector proteins involved in intracellular trafficking and cytoskeleton dynamics. Frontiers in Cell and Developmental Biology, August 2020. URL: http://dx.doi.org/10.3389/fcell.2020.00779, doi:10.3389/fcell.2020.00779. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2020.00779)

[4. (Terawaki2015RUN) Seigo Terawaki, Voahirana Camosseto, Francesca Prete, Till Wenger, Alexia Papadopoulos, Christiane Rondeau, Alexis Combes, Christian Rodriguez Rodrigues, Thien-Phong Vu Manh, Mathieu Fallet, Luc English, Rodrigo Santamaria, Ana R. Soares, Tobias Weil, Hamida Hammad, Michel Desjardins, Jean-Pierre Gorvel, Manuel A.S. Santos, Evelina Gatti, and Philippe Pierre. Run and fyve domain–containing protein 4 enhances autophagy and lysosome tethering in response to interleukin-4. Journal of Cell Biology, 210(7):1133–1152, September 2015. URL: http://dx.doi.org/10.1083/jcb.201501059, doi:10.1083/jcb.201501059. This article has 50 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1083/jcb.201501059)

[5. (KerenKaplan2022RUFY3) Tal Keren-Kaplan, Amra Sarić, Saikat Ghosh, Chad D. Williamson, Rui Jia, Yan Li, and Juan S. Bonifacino. Rufy3 and rufy4 are arl8 effectors that promote coupling of endolysosomes to dynein-dynactin. Nature Communications, March 2022. URL: http://dx.doi.org/10.1038/s41467-022-28952-y, doi:10.1038/s41467-022-28952-y. This article has 45 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-022-28952-y)

[6. (Kim2024RUFY4) Minhee Kim, Jin Hee Park, Miyeon Go, Nawon Lee, Jeongin Seo, Hana Lee, Doyong Kim, Hyunil Ha, Taesoo Kim, Myeong Seon Jeong, Suree Kim, Taesoo Kim, Han Sung Kim, Dongmin Kang, Hyunbo Shim, and Soo Young Lee. Rufy4 deletion prevents pathological bone loss by blocking endo-lysosomal trafficking of osteoclasts. Bone Research, May 2024. URL: http://dx.doi.org/10.1038/s41413-024-00326-8, doi:10.1038/s41413-024-00326-8. This article has 0 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41413-024-00326-8)